IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Jotte, Robert M.; Cappuzzo, Federico; Vynnychenko, Ihor; Stroyakovskiy, Daniil; Rodríguez‐Abreu, Delvys; Hussein, Maen; Soo, Ross A.; Conter, Henry Jacob; Kozuki, Toshiyuki; da Silva, Carlos Alberto

doi:10.1200/jco.2018.36.18_suppl.lba9000

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

NobleIDNI0P90W12R79S19

Type:Journal Article

0 views

Claim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/ACE82FE7.svg?ark=w1%2F20260521%2FACE82FE7&value=id)](https://nobleid.org/work/w1/20260521/ACE82FE7)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Delvys Rodríguez‐Abreu

Carlos Alberto da Silva

Claim authorship of this work

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

NobleIDNI0P90W12R79S19

Type:Journal Article

0 views

Claim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/ACE82FE7.svg?ark=w1%2F20260521%2FACE82FE7&value=id)](https://nobleid.org/work/w1/20260521/ACE82FE7)

ARK Inflections

Metadata (JSON)Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Delvys Rodríguez‐Abreu

Carlos Alberto da Silva

Claim authorship of this work